Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574860 · ClinicalTrials.gov registry record · Phase 3
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
A Phase 3 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00574860: Clinical Trial Phase 3 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00574860 is a Phase 3 study that was terminated before completion, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 240 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00574860, a Phase 3 study, was terminated before completion, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
Randomized, double-blind, placebo-controlled study for the treatment of head and neck cancer(HNC), to assess the ability of EN3285 to prevent or delay the onset of severe oral mucositis(OM).
Interventions
- DRUG Placebo
- OTHER Standard of care
- DRUG EN3285
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574860
The ClinicalTrials.gov registry entry for NCT00574860 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00574860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574860 about?
NCT00574860 is a clinical study titled "EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer". Randomized, double-blind, placebo-controlled study for the treatment of head and neck cancer(HNC), to assess the ability of EN3285 to prevent or delay the onset of severe oral mucositis(OM).
What is the current status of trial NCT00574860?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2007-12. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00574860?
The interventions under investigation include: Placebo (DRUG), Standard of care (OTHER), EN3285 (DRUG).
Who is sponsoring clinical trial NCT00574860?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.